Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell...

Area of Science:

• Immunology
• Oncology
• Gene Therapy

Background:

• Adoptive T-cell therapy is a promising cancer treatment.
• Current strategies often use CD8+ T cells or chimeric antigen receptors.
• MHC class II-restricted T-cell receptors (TCRs) offer an alternative approach.

Purpose of the Study:

• To evaluate the safety and efficacy of CD4+ T-cell therapy using an MHC class II-restricted TCR targeting MAGE-A3.
• To assess a MAGE-A3-specific TCR in patients with metastatic cancer.
• To explore the potential of HLA-DPB1*0401-restricted TCR gene therapy.

Main Methods:

• Adoptive transfer of CD4+ T cells genetically modified with a MAGE-A3 TCR.
• Administered to patients following lymphodepleting chemotherapy and high-dose IL-2.
• Conducted a dose escalation study from 10^7 to approximately 10^11 cells.

Main Results:

• Seventeen patients were treated; objective responses observed in cervical, esophageal, urothelial, and osteosarcoma cancers.
• A complete response in metastatic cervical cancer ongoing for ≥ 29 months.
• Transient toxicities included fevers and hematologic issues; no treatment-related deaths.

Conclusions:

• Autologous CD4+ T cells engineered with an MHC class II-restricted MAGE-A3 TCR are safe and effective.
• This approach expands the application of TCR gene therapy for metastatic cancers.
• Demonstrates the potential of targeting cancer germline antigens with engineered T cells.